Drug Trial Radar · NCT04924699
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
350
Planned (sponsor's estimate)
Start
Jun 30, 2021
Primary completion
Sep 2023
Study completion Oct 2023
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of Phase II is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive, unresectable locally advanced or metastatic breast cancer. The primary objective of Phase III is to evaluate the efficacy and safety of MRG002 versus Trastuzumab Emtansine (T-DM1) in patients with HER2-positive unresectable locally advanced or metastatic breast cancer who have been previously treated with trastuzumab (or a biosimilar) and an anti-HER2 tyrosine kinase inhibitor (anti-HER2-TKI) and have progressed on or after the most recent therapy.
Conditions
- Advanced Breast Cancer
- Metastatic Breast Cancer
Interventions
MRG002Drug
Administrated intravenously
Trastuzumab Emtansine for InjectionDrug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Independent Review Committee (IRC)Time frame: Baseline to study completion(up to 36 months)
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China · Active not recruiting
Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Active not recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Active not recruiting
The Fourth hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Active not recruiting
The First Affiliated Hosipital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Active not recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Active not recruiting
Xuzhou Central Hospital
Xuzhou, Jiangsu, China · Active not recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Active not recruiting
Liaoning Cancer Hospital & Institute
Shengyang, Liaoning, China · Active not recruiting
Jinan Central Hospital Affiliated to Shandong University
Jinan, Shandong, China · Active not recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjing, Tianjing, China · Active not recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Active not recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Active not recruiting
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.